Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629778 | 1.00 | TYMS (0.57) | TYMSCES1DNMT1CYP1A2TDP1 | |
| SCHEMBL26507159 | 0.82 | TYMS (0.41) | TYMSCES1DNMT1CYP1A2TDP1 | |
| SCHEMBL2353411 | 0.81 | CES1 (0.61) | TYMSCES1DNMT1CYP1A2TDP1 | |
| SCHEMBL6389286 | 0.78 | TYMS (0.41) | TYMSCES1DNMT1CYP1A2KDM4E | |
| SCHEMBL580216 | 0.78 | CES1 (0.65) | TYMSCES1DNMT1CYP1A2TDP1 | |
| SCHEMBL4958869 | 0.76 | ALOX5 (0.43) | TYMSCES1DNMT1TDP1TSHR | |
| SCHEMBL18676837 | 0.75 | KDM4E (0.60) | TYMSCES1CYP1A2TDP1POLB | |
| SCHEMBL4960932 | 0.75 | TYMS (0.40) | TYMSCES1DNMT1CYP1A2TSHR | |
| SCHEMBL29478287 | 0.73 | TYMS (1.00) | TYMSCYP1A2TDP1POLBERCC1 | |
| SCHEMBL29486055 | 0.73 | TYMS (1.00) | TYMSCYP1A2TDP1POLBERCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-2069308-B1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SER (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2069308-B1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SER (US) | 2017-03-29 | — | — | EP | disclosed |
| US-8008316-B2 | Azonafide derived tumor and cancer targeting compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008316-B2 | Azonafide derived tumor and cancer targeting compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008316-B2 | Azonafide derived tumor and cancer targeting compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100120817-A1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | Office of Technology Transfer, NIH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120817-A1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | Office of Technology Transfer, NIH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120817-A1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | Office of Technology Transfer, NIH (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008033891-A2 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-03-20 | — | — | WO | disclosed |
| US-5635506-A | ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0660824-A1 | 1,2 DIHYDRO-3-H-DIBENZ(de,h) ISOQUINOLINE 1,3 DIONE AND THEIR USE AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006771-A9 | 1,2 DIHYDRO-3-H-DIBENZ(de,h) ISOQUINOLINE 1,3 DIONE AND THEIR USE AS ANTICANCER AGENTS | — | 1994-06-09 | — | — | WO | disclosed |
| WO-1994006771-A1 | 1,2 DIHYDRO-3-H-DIBENZ(de,h) ISOQUINOLINE 1,3 DIONE AND THEIR USE AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120817-A1 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS | CDC73, MKI67, TP53 | TYMS 2258/4885CES1 1249/4885DNMT1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.